May 4, 2021
Transformative, leading allogeneic NKT cell platform technology expands Athenex’s cell therapy development capability Platform has broad applications based on transducing NKT…
Kuur TherapeuticsNews
January 21, 2021
Interim data from GINAKIT2 and ANCHOR clinical studies provide evidence of efficacy for Kuur’s chimeric antigen receptor-natural killer T cell (CAR-NKT)…
October 12, 2020
KUR-501 in Nature Medicine HOUSTON, TX– Oct 12, 2020 (BUSINESSWIRE) –Kuur Therapeutics, a leader in the development of off-the-shelf CAR-NKT cell…
September 29, 2020
Allogeneic “off-the-shelf” chimeric antigen receptor-natural killer T cell (CAR-NKT) therapy platform could overcome many of the challenges of current autologous CAR-T…
May 15, 2020
HOUSTON – May 15, 2020 – Kuur Therapeutics, a leader in the development of off-the-shelf CAR-NKT cell immunotherapies for the treatment…
March 10, 2020
New investments from IP Group, Baylor College of Medicine (BCM) and Schroeder Adveq Proceeds to fund phase 1 studies in both…